Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in KRAS
Study of RMC-6236 in Patients with Solid Tumors with a KRAS Mutation
Sponsor: Revolution Medicines
Enrolling: Male and Female Patients
IRB Number: AAAU3070
U.S. Govt. ID: NCT05379985
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to test an experimental drug called RMC-6236 (the study drug) for solid tumor cancer with a KRAS mutation. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of your cancer cells. RMC-6236 is an experimental drug, which means that it is not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC-6236 will be tested in humans. The safety of different doses of RMC-6236 and how it is processed by your body will be tested. Cancers include: bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer, ovarian cancer, head and neck/oral cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, testicular cancer, and thyroid cancer.
Benjamin Herzberg, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have a life expectancy of more than 3 months? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator